Scientific Publications
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
European Journal of Cancer 2021, 162: 107-117 (https://doi.org/10.1016/j.ejca.2021.11.030)
International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer.
Molecular Cancer Therapeutics 2021, 20: 1462–8 (https://doi.org/10.1158/1535-7163.MCT-20-0394)
Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers.
European Journal of Cancer 2020, 160:168-181 (https://doi.org/10.1016/j.ejca.2020.01.027)
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma.
Cancer Cell 2020, 38(1):44-59.e9. (https://doi.org/10.1016/j.ccell.2020.06.004)
Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity.
Nature Communication 2020, 11(1):4629. (https://doi.org/10.1038/s41467-020-18388-7)
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
Nature Medicine 2020, May 26(5):712-719. (https://doi.org/10.1038/s41591-020-0821-8)
Crossing Oceans: Preclinical Collaboration to Improve Pediatric Drug Development.
American Society of Clinical Oncology Educational Book. 2020, 40:1-8. (https://doi.org/10.1200/EDBK_278893)
Targeting fibroblast growth factor receptors to combat aggressive ependymoma.
Acta Neuropathologica 2021 Aug;142(2):339-360. (https://doi.org/10.1007/s00401-021-02327-x)
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma.
Cancer Research 2022, 82(4):708-720. (https://doi.org/10.1158/0008-5472.CAN-21-1222)
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Journal of Pathology–clinical research 2021, 7:338-349. (https://doi.org/10.1002/cjp2.210)
A biobank of patient-derived pediatric brain tumor models.
Nature Medicine 2018, 24: 1752–1761. (https://doi.org/10.1038/s41591-018-0207-3)
PCLN-05. A BIOBANK OF PATIENT-DERIVED MOLECULARLY CHARACTERIZED ORTHOTOPIC PEDIATRIC BRAIN TUMOR MODELS FOR PRECLINICAL RESEARCH.
Neuro-Oncology 2018, 20: 155 (https://doi.org/10.1093/neuonc/noy059.574)
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity.
Journal of Experimental & Clinical Cancer Research 2019, 38: 503 (https://doi.org/10.1186/s13046-019-1506-3)
TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma.
Acta Neuropathologica Communications 2019, 7: 128 (https://doi.org/10.1186/s40478-019-0775-6)
Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.
Translational Oncology 2020, 3: 221-232 (https://doi.org/10.1016/j.tranon.2019.09.013)
Increased Anaplastic Lymphoma Kinase Activity Induces a Poorly Differentiated Thyroid Carcinoma in Mice.
Thyroid 2020, 29/10: 1438-1446 (https://doi.org/10.1089/thy.2018.0526)
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Cancer Letters 2019, 445: 24-33 (https://doi.org/10.1016/j.canlet.2018.12.012)
Ewing Sarcoma PDX Models.
Ewing Sarcoma - Methods and Protocols 2020, 2226: 223-242 (https://doi.org/10.1007/978-1-0716-1020-6_18)
Molecular and preclinical evaluation of patient-derived orthotopic xenograft models of pediatric brain tumors.
Dissertation, Univesity of Heidelberg 2018. (https://d-nb.info/1199620114)